Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ingenol mebutate→

Ingenol Mebutate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
75567-37-2
PubChem CID
6918670
Molecular formula
C25H34O6
Molecular weight
430.5 g/mol
Drug class
Diterpene estertopical cytotoxic agent for actinic keratosis (withdrawn in EU)
Mechanism of action
Induces rapid cell death and inflammatory responses in treated epidermal cells. The precise molecular pathways are not fully defined; post-marketing evidence raised concerns about increased risk of skin malignancies.
Indications / reported uses
  • Historical topical indication: treatment of actinic keratosis in adults. The EU marketing authorisation for Picato was withdrawn in 2020 following concerns about skin malignancy risk; it should not be presented as a currently authorised EU treatment.

Sources: EMA — Picato referral and withdrawal decision · NLM MeSH — Ingenol mebutate · FDA product information

Identification source: PubChem record (CID 6918670). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Diterpene ester; topical cytotoxic agent for actinic keratosis (withdrawn in EU)

Mechanism of action

Induces rapid cell death and inflammatory responses in treated epidermal cells. The precise molecular pathways are not fully defined; post-marketing evidence raised concerns about increased risk of skin malignancies.

General use cases

  • Historical topical indication: treatment of actinic keratosis in adults. The EU marketing authorisation for Picato was withdrawn in 2020 following concerns about skin malignancy risk; it should not be presented as a currently authorised EU treatment.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Ingenol Mebutate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ingenol Mebutate Permitted Daily Exposure (PDE) report (the Ingenol Mebutate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ingenol Mebutate Occupational Exposure Limit (OEL) report (the Ingenol Mebutate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.